Nucleos(t)ide analogs constitute a diverse group of compounds derived from nucleosides and nucleotides, playing a crucial role in various biological processes. These analogs exhibit a wide range of applications, including their use as additives, antiviral, and anticancer agents, which makes them valuable in food and medical research. In this review, we will explore the applications of nucleos(t)ide analogs across different fields and discuss the latest advances in engineering and optimization strategies aimed at improving their production efficiency and tailoring their properties for specific purposes. The article focuses on the design of microbial cell factories and their critical role in the production of nucleos(t)ide analogs. By leveraging microbial biosynthesis pathways and employing strategies such as metabolic engineering, researchers are optimizing the synthesis pathways of nucleos(t)ide analogs. This optimization enhances both the yield and diversity of nucleos(t)ide analogs, leading to the creation of novel compounds with enhanced bioactivity and therapeutic potential. Consequently, these efforts are driving significant advancements in drug discovery and biotechnology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1040841X.2024.2435668 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection.
J Chin Med Assoc
December 2024
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Hepatitis B virus (HBV) infection is regarded as a major health concern worldwide. In patients with chronic HBV infection, exhausted virus-specific CD8+ T cells, resulting from the activation of the programmed cell death protein 1 and programmed death ligand 1 axis, play a key role in the chronicity of infection. Functional cure for HBV, defined as the seroclearance of hepatitis B surface antigen (HBsAg), is viewed as the optimal goal of chronic HBV infection treatment because HBsAg loss is associated with a low risk of hepatocellular carcinoma and a relatively favorable prognosis.
View Article and Find Full Text PDFA Sleeping Giant: Late HBV Reactivation After Rituximab-Based Chemotherapy Despite Correct Prophylaxis.
Int Med Case Rep J
December 2024
Clinical Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
Hepatitis B virus (HBV) reactivation is a recognized complication of long-term immunosuppressive or cytotoxic therapy, typically occurring during immunosuppression or within a few months after treatment. To mitigate this risk, hepatological societies recommend the use of nucleos(t)ide analogues (NA) for HBV reactivation prophylaxis, along with post-treatment monitoring; though, these recommendations are not universally consistent across different guidelines. We present a case of late HBV reactivation in a 76-year-old male with occult HBV infection who received rituximab-based therapy for chronic lymphocytic leukemia.
View Article and Find Full Text PDFDysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies.
Front Cell Infect Microbiol
December 2024
Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
In the context of chronic hepatitis B virus (HBV) infection, the continuous replication of HBV within host hepatocytes is a characteristic feature. Rather than directly causing hepatocyte destruction, this replication leads to immune dysfunction and establishes a state of T-B immune tolerance. Successful clearance of the HBV virus is dependent on the close collaboration between humoral and cellular immunity.
View Article and Find Full Text PDFDistinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy.
JHEP Rep
January 2025
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Background & Aims: The dynamics of HBV viral load (VL) in patients with chronic hepatitis B (CHB) on nucleos(t)ide analogue (NA) treatment and its relationship with liver disease are poorly understood. We aimed to study longitudinal VL patterns and their associations with CHB clinical outcomes.
Methods: Utilising large scale, routinely collected electronic health records from six centres in England, collated by the National Institute for Health and Care Research Health Informatics Collaborative (NIHR HIC), we applied latent class mixed models to investigate VL trajectory patterns in adults receiving NA treatment.
The Course of COVID-19 Infection in Patients With Chronic Hepatitis Delta.
J Viral Hepat
January 2025
Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.
In coronavirus disease 2019 (COVID-19), older age and co-morbidities are associated with mortality. Among liver disease aetiologies alcoholic liver disease was associated with mortality. Chronic hepatitis delta (CHD) had not been studied.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!